Experimental drugs for supraventricular tachycardia: an analysis of early phase clinical trials

References

• Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC guidelines for the management of patients with supraventricular tachycardiaThe task force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020 Feb 1;41(5):655–720. doi: 10.1093/eurheartj/ehz467
   PubMed Web of Science ®Google Scholar
• Morillo CA, Banerjee A, Perel P. Wood D atrial fibrillation: the current epidemic. J Geriatr Cardiol JGC. 2017 Mar;14(3):195–203. doi: 10.11909/j.issn.1671-5411.2017.03.011
   PubMedGoogle Scholar
• Schotten U, Verheule S, Kirchhof P, et al. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011 Jan;91(1):265–325. doi: 10.1152/physrev.00031.2009
   PubMed Web of Science ®Google Scholar
• Thijssen VL, Ausma J, Liu GS, et al. Structural changes of atrial myocardium during chronic atrial fibrillation. Cardiovasc Pathol Off J Soc Cardiovasc Pathol. 2000;9(1):17–28. doi: 10.1016/S1054-8807(99)00038-1
   PubMed Web of Science ®Google Scholar
• Bogousslavsky J, Cachin C, Regli F, et al. Cardiac sources of embolism and cerebral infarction–clinical consequences and vascular concomitants: the Lausanne stroke registry. Neurology. 1991 Jun;41(6):855–859. doi: 10.1212/WNL.41.6.855
   PubMed Web of Science ®Google Scholar
• Huizar JF, Ellenbogen KA, Tan AY, et al. Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019 May 14;73(18):2328–2344.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb 1;137(2):263–272.
   PubMed Web of Science ®Google Scholar
• Ramlawi B, Abu Saleh WK, Edgerton J. The left atrial appendage: target for stroke reduction in atrial fibrillation. Methodist Debakey Cardiovasc J. 2015 Apr;11(2):100–103. doi: 10.14797/mdcj-11-2-100
   PubMedGoogle Scholar
• Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000 Dec 1;36(7):2242–2246. doi: 10.1016/S0735-1097(00)00982-7
   PubMed Web of Science ®Google Scholar
• Spector P, Reynolds MR, Calkins H, et al. Meta-analysis of ablation of atrial flutter and supraventricular TachycardiaAm. Am J Cardiol. 2009 Sep 1;104(5):671–677. doi: 10.1016/j.amjcard.2009.04.040
   PubMed Web of Science ®Google Scholar
• Coffey JO, d’Avila A, Dukkipati S, et al. Catheter ablation of scar-related atypical atrial flutter. EUROPACE. 2013 Jan 1;15(3):414–419. doi: 10.1093/europace/eus312
   PubMed Web of Science ®Google Scholar
• Saoudi N, Cosio F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases - a statement from a joint expert group from the working group of arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001 Jul 1;22(14):1162–1182. doi: 10.1053/euhj.2001.2658
   PubMed Web of Science ®Google Scholar
• Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to Focal atrial tachycardia: long-term outcome after Catheter ablation. J Am Coll Cardiol. 2009 May 12;53(19):1791–1797. doi: 10.1016/j.jacc.2009.02.014
   PubMed Web of Science ®Google Scholar
• Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-white syndrome) by radiofrequency current. N Engl J Med. 1991 Jun 6;324(23):1605–1611. doi: 10.1056/NEJM199106063242301
   PubMed Web of Science ®Google Scholar
• Crijns HJGM, Elvan A, Al-Windy N, et al. Open-label, multicenter study of flecainide acetate oral inhalation solution for acute conversion of recent-onset, symptomatic atrial fibrillation to sinus rhythm. Circ: Arrhythmia And Electrophysiology. 2022 Mar;15(3):e010204. doi: 10.1161/CIRCEP.121.010204
   PubMed Web of Science ®Google Scholar
• Pabel S, Mustroph J, Stehle T, et al. Dantrolene reduces CaMKIIδC-mediated atrial arrhythmias. EP Europace. 2020 Jul 1;22(7):1111–1118. doi: 10.1093/europace/euaa079
   PubMed Web of Science ®Google Scholar
• Hartmann N, Pabel S, Herting J, et al. Antiarrhythmic effects of dantrolene in human diseased cardiomyocytes. Heart Rhythm. 2017 Mar 1;14(3):412–419. doi: 10.1016/j.hrthm.2016.09.014
   PubMed Web of Science ®Google Scholar
• Kim K, Blackwell DJ, Yuen SL, et al. The selective RyR2 inhibitor ent-verticilide suppresses atrial fibrillation susceptibility caused by Pitx2 deficiency. J Mol Cell Cardiol. 2023 Jul;180:1–9.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Belardinelli L, Chaitman BR, et al. Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Europace. 2015 Jan 1;17(1):32–37. doi: 10.1093/europace/euu217
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Sicouri S, Di Diego JM, et al. Synergistic effect of the combination of Ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010 Oct 5;56(15):1216–1224.
   PubMed Web of Science ®Google Scholar
• Fragakis N, Koskinas KC, Katritsis DG, et al. Comparison of effectiveness of Ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol. 2012 Sep 1;110(5):673–677. doi: 10.1016/j.amjcard.2012.04.044
   PubMed Web of Science ®Google Scholar
• Neef S, Mann C, Zwenger A, et al. Reduction of SR Ca2+ leak and arrhythmogenic cellular correlates by SMP-114, a novel CaMKII inhibitor with oral bioavailability. Basic Res Cardiol. 2017 Jun 13;112(4):45.
   PubMed Web of Science ®Google Scholar
• Mustroph J, Drzymalski M, Baier M, et al. The oral Ca/calmodulin-dependent kinase II inhibitor RA608 improves contractile function and prevents arrhythmias in heart failure. ESC Heart Fail. 2020;7(5):2871–2883. doi: 10.1002/ehf2.12895
   PubMed Web of Science ®Google Scholar
• Zhang J, Liang R, Wang K, et al. Novel CaMKII-δ inhibitor hesperadin exerts dual functions to ameliorate cardiac ischemia/reperfusion injury and inhibit tumor growth. Circ. 2022 Apr 12;145(15):1154–1168. doi: 10.1161/CIRCULATIONAHA.121.055920
   PubMed Web of Science ®Google Scholar
• Diness JG, Skibsbye L, Simó-Vicens R, et al. Termination of vernakalant-resistant atrial fibrillation by inhibition of small-conductance Ca2±Activated K+ channels in pigs. Circ Arrhythm Electrophysiol. 2017 Oct;10(10):e005125. doi: 10.1161/CIRCEP.117.005125
   PubMed Web of Science ®Google Scholar
• Gal P, Klaassen ES, Bergmann KR, et al. First clinical study with AP30663 - a KCa2 channel inhibitor in development for conversion of atrial fibrillation. Clinical Translational Sci. 2020;13(6):1336–1344. doi: 10.1111/cts.12835
   PubMed Web of Science ®Google Scholar
• Clinical Trials Register [Internet]. [cited 2023 Mar 20]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002979-17/DE
   Google Scholar
• Wiedmann F, Beyersdorf C, Zhou X, et al. Pharmacologic TWIK‐related acid‐sensitive K+ channel (TASK‐1) potassium channel inhibitor A293 facilitates acute cardioversion of paroxysmal atrial fibrillation in a porcine large animal model. J Am Heart Assoc. 2020 May 18;9(10):e015751. doi: 10.1161/JAHA.119.015751
   PubMed Web of Science ®Google Scholar
• Wiedmann F, Beyersdorf C, Zhou XB, et al. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Cardiovascular Research. 2022 May 15;118(7):1728–1741. doi: 10.1093/cvr/cvab177
   PubMed Web of Science ®Google Scholar
• Lee KW, Everett TH, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. 2006 Oct 17;114(16):1703–1712. doi: 10.1161/CIRCULATIONAHA.106.624320
   PubMed Web of Science ®Google Scholar
• Ferreira RR, da S Abreu R, Vilar-Pereira G, et al. TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas’ heart disease. PLoS Negl Trop Dis. 2019 Jul;13(7):e0007602. doi: 10.1371/journal.pntd.0007602
   PubMed Web of Science ®Google Scholar
• Harada M, Luo X, Qi XY, et al. Transient receptor potential canonical-3 channel–dependent fibroblast regulation in atrial fibrillation. Circulation. 2012 Oct 23;126(17):2051–2064. doi: 10.1161/CIRCULATIONAHA.112.121830
   PubMed Web of Science ®Google Scholar
• Li Yi Fei L, Lou Q, Liu GZ, et al. Sacubitril/Valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation. European Journal Of Pharmacology query. 2020 Aug 15;881:173120.
   PubMed Web of Science ®Google Scholar
• Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation | Circulation Research [Internet]. [cited 2023 May 19]. doi: 10.1161/CIRCRESAHA.121.319425
   Google Scholar
• Adam O, Theobald K, Lavall D, et al. Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation. J Mol Cell Cardiol. 2011 Apr 1;50(4):678–685. doi: 10.1016/j.yjmcc.2010.12.019
   PubMed Web of Science ®Google Scholar
• Yao C, Veleva T, Scott L, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation. 2018 Nov 13;138(20):2227–2242. doi: 10.1161/CIRCULATIONAHA.118.035202
   PubMed Web of Science ®Google Scholar
• Jesus NMD, Wang L, Lai J, et al. Antiarrhythmic effects of interleukin 1 inhibition after myocardial infarction. Heart Rhythm. 2017 May 1;14(5):727–736. doi: 10.1016/j.hrthm.2017.01.027
   PubMed Web of Science ®Google Scholar
• Aschar-Sobbi R, Izaddoustdar F, Korogyi AS, et al. Increased atrial arrhythmia susceptibility induced by intense endurance exercise in mice requires TNFα. Nat Commun. 2015 Jan 19;6(1):6018. doi: 10.1038/ncomms7018
   PubMedGoogle Scholar
• Camm AJ, Dorian P, Hohnloser SH, et al. A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. Eur Heart J - Cardiovasc Pharmacother. 2019 Jan 1;5(1):21–28. doi: 10.1093/ehjcvp/pvy022
   PubMed Web of Science ®Google Scholar
• Stambler BS, Plat F, Sager PT, et al. First randomized, multicenter, placebo-controlled study of self-administered intranasal Etripamil for acute conversion of spontaneous paroxysmal supraventricular tachycardia (NODE-301). Circ Arrhythm Electrophysiol. 2022 Dec;15(12):e010915. doi: 10.1161/CIRCEP.122.010915
   PubMed Web of Science ®Google Scholar
• Arora G Dexmedetomidine versus Adenosine: electrophysiologic effects and therapeutic use for terminating supraventricular tachycardia [Internet]. clinicaltrials.gov. 2017 Feb [cited 2023 May 18]. Report No.: NCT01495481. Available from: https://clinicaltrials.gov/ct2/show/NCT01495481
   Google Scholar
• MD AM A randomised controlled trial of the standard versus a simplified adenosine administration method in the treatment of adult patients with Supra- Ventricular Tachycardia (SVT) [Internet]. clinicaltrials.gov. 2021 Jun[cited 2023 May 18]. Report No.: NCT04392362. Available from: https://clinicaltrials.gov/ct2/show/NCT04392362
   Google Scholar
• Clinical Trials Register [Internet]. [cited 2023 May 19]. http://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002979-17/DE
   Google Scholar
• St. Vincent Cardiovascular Research Institute. Post-ablation pericarditis reduction study [Internet]. clinicaltrials.gov. 2022 Nov [cited 2023 May 18]. (Report No.: NCT04906720). Available from: https://clinicaltrials.gov/ct2/show/NCT04906720
   Google Scholar
• Population Health Research Institute. Colchicine for the prevention of perioperative atrial fibrillation in patients undergoing thoracic surgery (COP-AF) [Internet]. clinicaltrials.gov; 2022 Nov [cited 2023 May 18]. (Report No.: NCT03310125). Available from: https://clinicaltrials.gov/ct2/show/NCT03310125
   Google Scholar
• Bakulev Scientific Center of Cardiovascular Surgery. Colchicine for prevention atrial fibrillation after cardiac surgery in the early postoperative period [Internet]. clinicaltrials.gov; 2022 Nov [cited 2023 May 18]. (Report No.: NCT04224545). Available from: https://clinicaltrials.gov/ct2/show/NCT04224545
   Google Scholar
• Milestone Pharmaceuticals Inc. Multi-centre, randomized, double-blind, placebo-controlled, efficacy, and safety study of Etripamil nasal spray for the termination of spontaneous episodes of paroxysmal supraventricular tachycardia. NODE 301 trial. [Internet]. clinicaltrials.gov; 2023 Feb [cited 2023 Mar 16]. (Report No.: NCT03464019). Available from: https://clinicaltrials.gov/ct2/show/NCT03464019
   Google Scholar
• InCarda Therapeutics, Inc. A Phase 3, randomized, double-blind, placebo-controlled trial of flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation to sinus rhythm [Internet]. clinicaltrials.gov. 2022 Dec [cited 2023 May 18]. (Report No.: NCT05039359). Available from: https://clinicaltrials.gov/ct2/show/NCT05039359
   Google Scholar
• Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation. Circ: Arrhythmia And Electrophysiology. 2008 Apr;1(1):62–73. doi: 10.1161/CIRCEP.107.754564
   PubMed Web of Science ®Google Scholar
• Saljic A, Heijman J, Dobrev D. Emerging antiarrhythmic drugs for atrial fibrillation. IJMS. 2022 Jan;23(8):4096. doi: 10.3390/ijms23084096
   Google Scholar
• Hwang HS, Hasdemir C, Laver D, et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ: Arrhythmia And Electrophysiology. 2011 Apr;4(2):128–135. doi: 10.1161/CIRCEP.110.959916
   PubMed Web of Science ®Google Scholar
• Echt DS, Ruskin JN. Use of flecainide for the treatment of atrial fibrillation. The American Journal Of Cardiology. 2020 Apr 1;125(7):1123–1133.
   PubMed Web of Science ®Google Scholar
• Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med. 1991 Mar 21;324(12):781–788. doi: 10.1056/NEJM199103213241201
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Wakeyama T, Ono S, et al. A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design. Journal Of Cardiology. 2020 Apr 1;75(4):454–461. doi: 10.1016/j.jjcc.2019.08.020
   PubMed Web of Science ®Google Scholar
• Lynch CI, Durbin CGJ, Fisher NA, et al. Effects of dantrolene and verapamil on atrioventricular conduction and Cardiovascular performance in dogs. Anesthesia & Analgesia. 1986 Mar;65(3):252. doi: 10.1213/00000539-198603000-00006
   PubMed Web of Science ®Google Scholar
• Ranolazine: electrophysiologic effect, efficacy, and safety in patients with cardiac arrhythmias - ClinicalKey [Internet]. [cited 2023 Mar 19]. Available from: https://www-clinicalkey-com.eresources.mssm.edu/#!/content/playContent/1-s2.0-S1877918216300181?returnurl=null&referrer=null
   Google Scholar
• Parikh A, Mantravadi R, Kozhevnikov D, et al. Ranolazine stabilizes cardiac Ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsade de pointes in long QT type 2. Heart Rhythm. 2012 Jun;9(6):953–960. doi: 10.1016/j.hrthm.2012.01.010
   PubMed Web of Science ®Google Scholar
• Reiffel JA, Camm AJ, Belardinelli L, et al. The HARMONY trial: combined Ranolazine and Dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic Synergism. Circ: Arrhythmia And Electrophysiology. 2015 Oct;8(5):1048–1056. doi: 10.1161/CIRCEP.115.002856
   PubMed Web of Science ®Google Scholar
• Koskinas KC, Fragakis N, Katritsis D, et al. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace. 2014 Jul 1;16(7):973–979.
   PubMed Web of Science ®Google Scholar
• Rayner‐Hartley E, Sedlak T. Ranolazine: a contemporary review. J Am Heart Assoc Internet. 2016 Mar 15 [cited 2023 Apr 19];5(3). doi: 10.1161/JAHA.116.003196
   PubMed Web of Science ®Google Scholar
• Mustroph J, Neef S, Maier LS. CaMKII as a target for arrhythmia suppression. Pharmacology & Therapeutics. 2017 Aug 1;176:22–31. doi: 10.1016/j.pharmthera.2016.10.006.
   PubMed Web of Science ®Google Scholar
• Saljic A, Jespersen T, Buhl R. Anti-arrhythmic investigations in large animal models of atrial fibrillation. Br J Pharmacol. 2022;179(5):838–858. doi: 10.1111/bph.15417
   PubMed Web of Science ®Google Scholar
• Xu Y, Tuteja D, Zhang Z, et al. Molecular identification and functional roles of a Ca2±activated K+ channel in human and mouse hearts *. J Biol Chem. 2003 Dec 5;278(49):49085–49094. doi: 10.1074/jbc.M307508200
   PubMed Web of Science ®Google Scholar
• Skibsbye L, Poulet C, Diness JG, et al. Small-conductance calcium-activated potassium (SK) channels contribute to action potential repolarization in human atria. Cardiovasc Res. 2014 Jul 1;103(1):156–167. doi: 10.1093/cvr/cvu121
   PubMed Web of Science ®Google Scholar
• Acesion Pharma. A double-blind, randomised, placebo-controlled, parallel-group study of AP30663 given intravenously for cardioversion in patients with atrial fibrillation [Internet]. clinicaltrials.gov. 2022 Jun [cited 2023 Mar 16]. (Report No.: NCT04571385). Available from: https://clinicaltrials.gov/ct2/show/NCT04571385
   Google Scholar
• Heijman J, Ghezelbash S, Dobrev D. Investigational antiarrhythmic agents: promising drugs in early clinical development. Expert Opinion On Investigational Drugs. 2017 Aug 3;26(8):897–907.
   PubMed Web of Science ®Google Scholar
• El-Haou S, Ford JW, Milnes JT. Novel K+ channel targets in atrial fibrillation drug development–where are we? J Cardiovasc Pharmacol. 2015 Nov;66(5):412–431. doi: 10.1097/FJC.0000000000000277
   PubMed Web of Science ®Google Scholar
• Flaherty DP, Simpson DS, Miller M, et al. Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-amide scaffold. Bioorganic & Medicinal Chemistry Letters. 2014 Aug 15;24(16):3968–3973. doi: 10.1016/j.bmcl.2014.06.032
   PubMed Web of Science ®Google Scholar
• Wiedmann F, Beyersdorf C, Zhou XB, et al. The experimental TASK-1 potassium channel inhibitor A293 can be employed for rhythm control of persistent atrial fibrillation in a translational large animal model. Front Physiol Internet. 2021 [cited 2023 May 17];11. doi: 10.3389/fphys.2020.629421
   Google Scholar
• Tsuji Y, Dobrev D. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update. Vasc Health Risk Manag. 2013;9:165–175. doi: 10.2147/VHRM.S43720
   PubMedGoogle Scholar
• Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011 Jan 18;57(3):313–321. doi: 10.1016/j.jacc.2010.07.046
   PubMed Web of Science ®Google Scholar
• Roy D, Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am College Cardiol. 2004 Dec 21;44(12):2355–2361. doi: 10.1016/j.jacc.2004.09.021
   PubMed Web of Science ®Google Scholar
• Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation. Circulation. 2008 Mar 25;117(12):1518–1525. doi: 10.1161/CIRCULATIONAHA.107.723866
   PubMed Web of Science ®Google Scholar
• Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery. Circ Arrhythm Electrophysiol. 2009 Dec;2(6):652–659. doi: 10.1161/CIRCEP.109.870204
   PubMed Web of Science ®Google Scholar
• Pratt CM, Roy D, Torp-Pedersen C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010 Nov 1;106(9):1277–1283. doi: 10.1016/j.amjcard.2010.06.054
   PubMed Web of Science ®Google Scholar
• Stiell IG, Roos JS, Kavanagh KM, et al. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J. 2010 Jun 1;159(6):1095–1101. doi: 10.1016/j.ahj.2010.02.035
   PubMed Web of Science ®Google Scholar
• Lévy S, Hartikainen J, Ritz B, et al. Vernakalant for rapid cardioversion of recent-onset atrial fibrillation: results from the SPECTRUM study. Cardiovasc Drugs Ther. 2021 Apr 1;35(2):283–292.
   PubMed Web of Science ®Google Scholar
• Liu P, Li K, Wang S, et al. Meta‑analysis of the efficacy and safety of nifekalant in the conversion of atrial fibrillation. Exp Ther Med. 2023 Jan 1;25(1):1–9.
   PubMed Web of Science ®Google Scholar
• Olschewski A, Li Y, Tang B, et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res. 2006 Apr 28;98(8):1072–1080. doi: 10.1161/01.RES.0000219677.12988.e9
   PubMed Web of Science ®Google Scholar
• Ward JW, Gilbert DL, Franko BV, et al. Toxicologic studies of doxapram hydrochloride. Toxicol Appl Pharmacol. 1968 Sep 1;13(2):242–250.
   Web of Science ®Google Scholar
• Ford J, Milnes J, Haou SE, et al. The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation. Heart Rhythm. 2016 Feb 1;13(2):555–564. doi: 10.1016/j.hrthm.2015.10.003
   PubMed Web of Science ®Google Scholar
• Podd SJ, Freemantle N, Furniss SS, et al. First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation. Europace. 2016 Mar 1;18(3):340–346.
   PubMed Web of Science ®Google Scholar
• Koruth JS, Lala A, Pinney S, et al. The clinical use of ivabradine. J Am Coll Cardiol. 2017 Oct 3;70(14):1777–1784.
   PubMed Web of Science ®Google Scholar
• Roberts-Thomson KC, Kistler PM, Kalman JM. Focal atrial tachycardia I: clinical features, diagnosis, mechanisms, and anatomic location. Pacing Clin Electrophysiol. 2006;29(6):643–652. doi: 10.1111/j.1540-8159.2006.00413.x
   PubMed Web of Science ®Google Scholar
• Roberts-Thomson KC, Kistler PM, Kalman JM. Focal atrial tachycardia II: management. Pacing Clin Electrophysiol. 2006;29(7):769–778. doi: 10.1111/j.1540-8159.2006.00433.x
   PubMed Web of Science ®Google Scholar
• Banavalikar B, Shenthar J, Padmanabhan D, et al. Clinical and electrophysiological correlates of incessant ivabradine-sensitive atrial tachycardia. Circ: Arrhythmia And Electrophysiology. 2019 Aug;12(8):e007387. doi: 10.1161/CIRCEP.119.007387
   PubMed Web of Science ®Google Scholar
• Meles E, Carbone C, Maggiolini S, et al. A case of atrial tachycardia treated with Ivabradine as bridge to ablation. J Cardiovasc Electrophysiol. 2015;26(5):565–568. doi: 10.1111/jce.12636
   PubMed Web of Science ®Google Scholar
• Bohora S, Lokhandwala Y, Parekh P, et al. Reversal of tachycardiomyopathy due to left atrial tachycardia by Ivabradine. J Cardiovasc Electrophysiol. 2011;22(3):340–342. doi: 10.1111/j.1540-8167.2010.01860.x
   PubMed Web of Science ®Google Scholar
• Janson CM, Tan RB, Iyer VR, et al. Ivabradine for treatment of tachyarrhythmias in children and young adults. Heart Rhythm Case Rep. 2019 Jun 1;5(6):333–337.
   PubMedGoogle Scholar
• Walsh EP, Saul JP, Sholler GF, et al. Evaluation of a staged treatment protocol for rapid automatic junctional tachycardia after operation for congenital heart disease. J Am Coll Cardiol. 1997 Apr 1;29(5):1046–1053. doi: 10.1016/S0735-1097(97)00040-5
   PubMed Web of Science ®Google Scholar
• Al-Ghamdi S, Al-Fayyadh MI, Hamilton RM. Potential new indication for Ivabradine: treatment of a patient with congenital junctional ectopic tachycardia. J Cardiovasc Electrophysiol. 2013;24(7):822–824. doi: 10.1111/jce.12081
   PubMed Web of Science ®Google Scholar
• Dieks JK, Klehs S, Müller MJ, et al. Adjunctive ivabradine in combination with amiodarone: a novel therapy for pediatric congenital junctional ectopic tachycardia. Heart Rhythm. 2016 Jun 1;13(6):1297–1302. doi: 10.1016/j.hrthm.2016.03.015
   PubMed Web of Science ®Google Scholar
• Krishna MR, Kunde MF, Kumar RK, et al. Ivabradine in post-operative junctional ectopic tachycardia (JET): breaking new ground. Pediatr Cardiol. 2019 Aug;40(6):1284–1288. doi: 10.1007/s00246-019-02149-5
   PubMed Web of Science ®Google Scholar
• Kumar V, Kumar G, Tiwari N, et al. Ivabradine as an adjunct for refractory junctional ectopic tachycardia following pediatric cardiac surgery: a preliminary study. World J Pediatr Congenit Heart Surg. 2019 Nov 1;10(6):709–714.
   PubMed Web of Science ®Google Scholar
• Plat F, Broughton A, Douville P, et al. Abstract 19713: the electrocardiographic effects of intranasal formulations of a new calcium channel blocker, MSP-2017, are consistent with a potential treatment of paroxysmal supraventricular tachycardia: results of a Phase I dose escalation study. Circ. 2015 Nov 10;132(suppl_3):A19713–A19713.
   Google Scholar
• Stambler BS, Dorian P, Sager PT, et al. Etripamil nasal spray for rapid conversion of supraventricular tachycardia to sinus rhythm. J Am Coll Of Cardiol. 2018 Jul 31;72(5):489–497. doi: 10.1016/j.jacc.2018.04.082
   PubMed Web of Science ®Google Scholar